Below is my response to H_dog_taco on the other board. Much is being said about possible joint ventures and mergers. Somehow they think that because Stanley Hirsch is the COB of both Foamix and OWC, it's a foregone conclusion that at some point this may become a reality. Being the prick that he is, that may very well suit his original agenda of building "massive value" for himself and screw shareholders in the process. Good news is that notwithstanding his title, he has limited influence with OWC, and very little with Foamix. David Domzalski, their CEO calls all the shots. Also it's not a certainty that Stanley Hirsch will continue to be on the BOD, let alone be its chairman.
Response to H_dog_taco:
You’ve raised some issues that are being talked about a lot. Below are my observations and clarification to some of them.
1: The marketing/sales lady being referred to is Miri Chen. She may have a lot of connections, but the last time I checked she was looking for a job. Her linkedin states that she is “seeking for new opportunity in Marketing/Buisness Development in the Pharma/Medical Device/Medical Cannabis industry”. https://il.linkedin.com/in/mirichen?trk=publi...full-click
2: Cannot argue with your comment that they treat “current shareholders like complete shit”.
3: We continue to check their website and it is true that the company has really no interest in updating it. It’s also true that their twitter page has gone MIA. The login info remains with their so-called former advisor from Florida, aka a certified idiot. If you look at the bottom right of the company’s website you will notice a linkedin link. The link gives us the names of two employees at OWC Pharma. One is Yonit Tsarfati, listed as a Project Manager, and the other is Hilla Kochavi, listed as the Manager of Marketing at Kinarti. Hilla also goes by the name Hilla Kochavi-Zeevi. I believe their last post and reference to OWC was back in September. It’s obvious their position, if you want to call it that, with OWC is very informal and part-time.
4: To me it doesn’t scream a buyout/merger, not yet anyway.
5: OWC Pharma did not bail on the Stenocare MOU. It was the other way around. However, in retrospect my view on that is that OWC Pharma is better off without Stenocare. Especially considering that since the announcement they received the patent grant. They are now free to pursue other options, whatever those may be.
6: I sure as hell hope that Foamix stays away from OWC Pharma. Not everybody is happy with the Menlo Therapeutics merger. The exchange of shares between the two companies translates to an 18% premium to Menlo Shareholders. That is the good news and the best-case scenario. Built into the agreement is a contingent stock right that hinges on the result of two phase 3 clinical trials. A lot of fingers will be crossed!
http://www.foamix.com/news-releases/news-rele...ed-company
7: Speaking of crossed fingers, some of us have crossed them for so long that they have become permanently fused. As a consequence I’ve stopped believing in tea leaves!
8: Yes, the best advice is to do your own DD and take all the hype and riff raff with a grain of salt.
Response to H_dog_taco:
You’ve raised some issues that are being talked about a lot. Below are my observations and clarification to some of them.
1: The marketing/sales lady being referred to is Miri Chen. She may have a lot of connections, but the last time I checked she was looking for a job. Her linkedin states that she is “seeking for new opportunity in Marketing/Buisness Development in the Pharma/Medical Device/Medical Cannabis industry”. https://il.linkedin.com/in/mirichen?trk=publi...full-click
2: Cannot argue with your comment that they treat “current shareholders like complete shit”.
3: We continue to check their website and it is true that the company has really no interest in updating it. It’s also true that their twitter page has gone MIA. The login info remains with their so-called former advisor from Florida, aka a certified idiot. If you look at the bottom right of the company’s website you will notice a linkedin link. The link gives us the names of two employees at OWC Pharma. One is Yonit Tsarfati, listed as a Project Manager, and the other is Hilla Kochavi, listed as the Manager of Marketing at Kinarti. Hilla also goes by the name Hilla Kochavi-Zeevi. I believe their last post and reference to OWC was back in September. It’s obvious their position, if you want to call it that, with OWC is very informal and part-time.
4: To me it doesn’t scream a buyout/merger, not yet anyway.
5: OWC Pharma did not bail on the Stenocare MOU. It was the other way around. However, in retrospect my view on that is that OWC Pharma is better off without Stenocare. Especially considering that since the announcement they received the patent grant. They are now free to pursue other options, whatever those may be.
6: I sure as hell hope that Foamix stays away from OWC Pharma. Not everybody is happy with the Menlo Therapeutics merger. The exchange of shares between the two companies translates to an 18% premium to Menlo Shareholders. That is the good news and the best-case scenario. Built into the agreement is a contingent stock right that hinges on the result of two phase 3 clinical trials. A lot of fingers will be crossed!
http://www.foamix.com/news-releases/news-rele...ed-company
7: Speaking of crossed fingers, some of us have crossed them for so long that they have become permanently fused. As a consequence I’ve stopped believing in tea leaves!
8: Yes, the best advice is to do your own DD and take all the hype and riff raff with a grain of salt.
1
